

Supplementary Table 2. Characteristics Patients with UC and CD after Propensity Score Matching

Characteristics		Only UC group (n = 82)	UC-AS group (n = 41)	P-value	Only CD group (n = 28)	CD-AS group (n = 14)	P-value
Age (yr)		44.9 ± 14.0	42.8 ± 15.1	0.309	43.7 ± 12.0	42.3 ± 12.3	0.727
Age at inflammatory bowel disease diagnosis (yr)		33.3 ± 12.3	31.1 ± 15.2	0.160	27.7 ± 10.6	33.5 ± 11.1	0.106
Sex	Male	53 (64.6)	26 (63.4)	1.000	22 (78.6)	10 (71.4)	0.707
	Female	29 (35.4)	15 (36.6)		6 (21.4)	4 (28.6)	
Surgery	No	76 (92.7)	38 (92.7)	1.000	16 (57.1)	11 (78.6)	0.306
	Yes	6 (7.3)	3 (7.3)		12 (42.9)	3 (21.4)	
	1	4 (66.7)	1 (33.3)	0.358	6 (50.0)	1 (33.3)	0.164
	2	2 (33.3)	0		0	2 (66.7)	
	3	0	1 (33.3)		3 (25.0)	0	
	4	0	1 (33.3)		2 (16.7)	0	
	5	0	0		1 (8.3)	0	
Bowel resection	No	79 (96.3)	38 (92.7)	0.399	20 (71.4)	11 (78.6)	0.723
	Yes	3 (3.7)	3 (7.3)		8 (28.6)	3 (21.4)	
	1	3 (100.0)	3 (100.0)	0.399	6 (75.0)	1 (33.3)	0.417
	2	0	0		1 (12.5)	2 (66.7)	
	3	0	0		1 (12.5)	0	
Emergency room	No	64 (78.0)	31 (75.6)	0.939	11 (39.3)	11 (78.6)	0.038
	Yes	18 (22.0)	10 (24.4)		17 (60.7)	3 (21.4)	
	1	11 (61.1)	5 (50.0)	0.660	5 (29.4)	0	0.073
	2	5 (27.8)	1 (10.0)		5 (29.4)	1 (33.3)	
	3	1 (5.6)	0		3 (17.6)	0	
	4	0	3 (30.0)		0	0	
	5	0	0		2 (11.8)	0	
	≥6	1 (5.6)	1 (10.0)		2 (11.8)	2 (66.7)	
Biologics or small molecules	No	78 (95.1)	28 (68.3)	<0.001	20 (71.4)	12 (85.7)	0.451
	Yes	4 (4.9)	13 (31.7)		8 (28.6)	2 (14.3)	
	1	3 (75.0)	8 (61.5)	<0.001	4 (50.0)	2 (100.0)	0.456
	2	1 (25.0)	3 (23.1)		4 (50.0)	0	
	3	0	1 (0.0)		0	0	
	5	0	1 (0.0)		0	0	
Immunomodulators	No	70 (85.4)	33 (80.5)	0.068	5 (17.9)	5 (35.7)	0.259
	Yes	12 (14.6)	8 (19.5)		23 (82.1)	9 (64.3)	
	1	9 (75.0)	1 (12.5)	0.016	10 (43.5)	0	0.028
	2	3 (25.0)	7 (87.5)		13 (56.5)	9 (100.0)	
Hypertension	No	80 (97.6)	39 (95.1)	0.600	28 (100.0)	13 (92.9)	0.333
	Yes	2 (2.4)	2 (4.9)		0	1 (7.1)	
Type 2 DM	No	77 (93.9)	40 (97.6)	0.662	27 (96.4)	13 (92.9)	1.000
	Yes	5 (6.1)	1 (2.4)		1 (3.6)	1 (7.1)	
Dyslipidemia	No	82 (100.0)	40 (97.6)	0.333	27 (96.4)	14 (100.0)	1.000
	Yes	0	1 (2.4)		1 (3.6)	0	

(Continued to the next page)

Supplementary Table 2. Continued

Characteristics		Only UC group (n = 82)	UC-AS group (n = 41)	P-value	Only CD group (n = 28)	CD-AS group (n = 14)	P-value
Immune-mediated disease ^a	No	77 (93.9)	38 (92.7)	1.000	27 (96.4)	12 (85.7)	0.254
	Yes	5 (6.1)	3 (7.3)		1 (3.6)	2 (14.3)	
Gastrointestinal cancer	No	81 (98.8)	41 (100.0)	1.000	28 (100.0)	14 (100.0)	1.000
	Yes	1 (1.2)	0		0	0	

Values are presented as mean ± standard deviation or number (%).

^aImmune-mediated disease included Behçet's disease, Wegener's disease, systemic lupus, multiple sclerosis, polymyositis, autoimmune hemolytic anemia, thrombocytopenic purpura, Henoch-Schonlein purpura, vitiligo, Grave's disease, type 1 DM, psoriasis, erythema nodosum, pyoderma gangrenosum, celiac disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, polymyalgia rheumatica, rheumatoid arthritis, hidradenitis. UC, ulcerative colitis; CD, Crohn's disease; AS, ankylosing spondylitis; DM, diabetes mellitus.